Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in the same period last year [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [10] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later in 2025, aiming to diversify its product offerings [6] - InMode remains committed to maintaining its workforce and not cutting costs, believing this will position the company to lead when market conditions improve [5] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] Other Important Information - InMode completed a share repurchase program, buying back 6.95 million shares for $127 million, returning over $412 million to shareholders in the past year [7] - The company has a strong balance sheet with cash and equivalents totaling $512.9 million as of March 31, 2025 [12] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [19] Question: Guidance for Q2 and market recovery - Management expressed optimism for Q2 but noted that if results do not improve significantly, guidance may need to be lowered [30] Question: Impact of tariffs on gross margins - Management explained that current tariffs could impact gross margins by approximately 2% to 3% if they remain at 10% [56] Question: Updates on operating expenses - Management confirmed that they plan to maintain investments in sales and marketing despite macro challenges [63] Question: Pricing strategy in the current market - Management decided against raising prices due to the current market conditions, emphasizing the importance of maintaining competitiveness [70] Question: Performance in Europe compared to the U.S. - Management noted that Europe performed better in Q1 2025, attributed to management changes and pricing strategies [83]

Core Insights - Eyes On Park has introduced the Envision by InMode system, a revolutionary non-invasive technology for advanced dry eye treatment in New York City [1][4][17] - The system combines Forma-I radiofrequency and Lumecca-I intense pulsed light therapies to address the root causes of dry eye disease, improving patient outcomes significantly [3][16] Treatment Technology - The Envision system utilizes two complementary technologies: Forma-I radiofrequency technology and Lumecca-I intense pulsed light therapy [5][7] - Forma-I delivers bipolar radiofrequency energy to enhance blood circulation and stimulate natural healing processes, particularly effective for meibomian gland dysfunction [6][11] - Lumecca-I uses intense pulsed light to reduce inflammation and improve symptoms in patients with inflammatory dry eye and ocular rosacea [7][12] Treatment Benefits - Patients typically experience noticeable improvement after just one session, with optimal results achieved after a series of treatments [15][16] - The Envision system provides a non-invasive treatment option that requires no downtime, allowing patients to resume normal activities immediately [15][16] Personalized Care - Treatment plans are customized based on comprehensive diagnostic testing, including advanced K5M diagnostic scans, allowing for tailored approaches to each patient's specific needs [14][15] - The practice emphasizes that no two cases of dry eye disease are identical, leading to higher patient satisfaction through targeted treatment [15] Availability - The Envision by InMode system is now available at Eyes On Park, and patients can schedule consultations to determine the suitability of this advanced treatment [17][18]

Company Overview - InMode is a leading global provider of minimally-invasive aesthetic and wellness solutions[4] - The company has a broad radiofrequency (RF) based portfolio, including capital equipment and consumables[4] - InMode sells in 90 countries[6] - The company has 641 employees worldwide, including 281 direct sales reps[11] Q1 2025 Financial Highlights - Q1 2025 revenue was $77.9 million[6] - Q1 2025 Non-GAAP net income was $21.4 million[6] - Q1 2025 Non-GAAP gross margin was 79%[6] - Q1 2025 Non-GAAP diluted earning per share was $0.31[6] Technology and Market - InMode addresses the "Treatment Gap" between laser procedures and plastic surgery with minimally-invasive technologies[17, 18] - Clinical studies demonstrate RFAL technology can achieve up to 40% contraction of the heated tissue volume[32]

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] - The company ended the quarter with cash and cash equivalents of $512.9 million [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in Q1 2024 [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [9] - Europe was the largest revenue contributor outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later this year, reflecting its strategy to diversify offerings [6] - InMode has committed to not reducing its workforce and aims to lead the industry during the market rebound [6] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company remains optimistic about a recovery in consumer interest in minimally invasive procedures as macro conditions stabilize [5] - Management expects operating margins to decrease by 4% to 5% due to market pressures and U.S. tariffs [13] Other Important Information - InMode returned over $412 million to shareholders through share repurchases over the past twelve months, representing approximately 27% of total capital [7] - The company anticipates a potential impact of 2% to 3% on gross margins due to U.S. tariffs [14] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [20][21] Question: Guidance for Q2 and market trends - Management is optimistic about Q2 but will adjust guidance if results do not improve significantly compared to Q1 [30][31] Question: Impact of the macroeconomic environment on guidance - Management reiterated that guidance remains unchanged for now, pending Q2 results [39] Question: Updates on U.S. management structure - The company has not yet hired a new President for the U.S. and management is actively involved in operations [66] Question: Tariff impact and pricing strategy - Management decided not to raise prices due to market conditions, despite tariff impacts [70][71] Question: Performance in Europe - Europe performed better than the U.S. in Q1, attributed to management changes and pricing strategies [84]

Core Insights - InMode reported quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.33 per share, and down from $0.45 per share a year ago, representing an earnings surprise of -6.06% [1] - The company posted revenues of $77.87 million for the quarter, surpassing the Zacks Consensus Estimate by 0.61%, but down from $80.28 million year-over-year [2] - InMode has surpassed consensus revenue estimates four times over the last four quarters, while it has exceeded EPS estimates only twice [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.50 on revenues of $100.1 million, and for the current fiscal year, it is $1.83 on revenues of $383.8 million [7] - The estimate revisions trend for InMode is currently unfavorable, leading to a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which InMode belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact InMode's stock performance [5]

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] - The company ended the quarter with cash and cash equivalents of $512.9 million [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in Q1 2024 [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [9] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later this year, reflecting its strategy to diversify offerings [6] - InMode has committed to not reducing its workforce and aims to lead the industry during the market rebound [6] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] - Management remains optimistic about a market recovery, contingent on Q2 performance [30] Other Important Information - InMode returned over $412 million to shareholders through share repurchases over the past twelve months, representing approximately 27% of total capital [7] - The company has not yet hired a new President for the U.S. and is currently led by the acting President [66] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [20][21] Question: Guidance for Q2 and market trends - Management expects Q2 to be stronger than Q1, but if results do not improve, guidance may need to be lowered [31][40] Question: Impact of tariffs on guidance - Tariffs are expected to impact gross margins by approximately 2% to 3% if they remain at 10% [57][79] Question: Updates on operating expenses - The company plans to maintain its investment in sales and marketing despite macro challenges, which may impact profitability [65] Question: Pricing strategy in the current market - Management decided not to raise prices due to the current market conditions, despite tariff impacts [70][90] Question: Performance in Europe compared to the U.S. - Europe has shown better performance due to management changes and pricing strategies, although credit conditions are tightening [83]

Core Viewpoint - InMode Ltd. reported a decline in revenues and net income for Q1 2025 compared to Q1 2024, attributed to a challenging macroeconomic environment and weakened consumer demand, while maintaining a strong focus on innovation and capital allocation strategies [4][10]. Financial Performance - Total GAAP revenues for Q1 2025 were $77.9 million, a decrease of 3% from $80.3 million in Q1 2024 [8]. - GAAP net income for Q1 2025 was $18.2 million, or $0.26 per diluted share, down from $23.7 million, or $0.28 per diluted share in Q1 2024 [10]. - Non-GAAP net income for Q1 2025 was $21.4 million, or $0.31 per diluted share, compared to $27.7 million, or $0.32 per diluted share in Q1 2024 [10]. Margins and Expenses - GAAP gross margin for Q1 2025 was 78%, down from 80% in Q1 2024, while non-GAAP gross margin was 79%, also down from 80% [8]. - GAAP operating margin decreased to 20% in Q1 2025 from 23% in Q1 2024, with non-GAAP operating margin dropping to 23% from 27% [9]. Shareholder Returns - The company completed a share repurchase program of 6.95 million shares for a total of $127 million, returning over $412 million to shareholders in the past 12 months, representing approximately 27% of its share capital [5][6]. Cash Position - As of March 31, 2025, InMode had a total cash position of $512.9 million, including cash and cash equivalents, marketable securities, and short-term bank deposits [11]. International Performance - InMode achieved record revenue in Europe during Q1 2025, despite ongoing market headwinds, indicating strong international performance [4]. Future Outlook - Management anticipates continued challenges in the U.S. market, projecting a 4%-5% decline in operating margins and an expected impact of 2%-3% on gross margins due to U.S. tariffs [7]. - The company has revised its 2025 financial outlook, expecting revenues between $395 million and $405 million, with non-GAAP gross margins between 78% and 80% [16].

Core Viewpoint - InMode Ltd. is set to release its financial results for the first quarter of 2025 on April 28, 2025, with preliminary revenue expectations ranging from $77.2 million to $77.5 million and a projected non-GAAP gross margin of 78% to 79% [6][2]. Financial Results - The company anticipates first quarter 2025 revenue to be between $77.2 million and $77.5 million [6]. - The projected non-GAAP gross margin for the same period is expected to be in the range of 78% to 79% [6]. - For the full year 2025, InMode expects revenue to be between $395 million and $405 million [6]. Conference Call Details - A conference call to discuss the first quarter 2025 financial results will take place on April 28, 2025, at 8:30 a.m. Eastern Daylight Time [3]. - Key management personnel, including the CEO, CFO, and CTO, will present during the call [3]. - Participants are encouraged to pre-register for the call to receive unique dial-in information [4]. Company Overview - InMode is recognized as a leading global provider of innovative medical technologies, focusing on devices that utilize novel radio frequency technology [6][7]. - The company aims to enhance surgical procedures and improve existing treatments across various medical fields, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology [6][7].

InMode (INMD) shares ended the last trading session 6.8% higher at $15.46. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 23% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This maker of cosmetic surgery devices is expected to post quarterly earnings of $0.45 per share in its upcoming ...

Core Insights - The article discusses the author's previous recommendation of InMode (NASDAQ: INMD) as a Hold due to concerns over management's capital allocation efficiency [1]. Group 1 - The author has over 10 years of experience in analyzing and publishing reports on companies in Brazil, Chile, and the United States [1]. - The focus of the author's analysis is primarily on small-cap companies, utilizing a deep value investment approach [1]. - The current strategy involves managing a personal portfolio and that of close friends, emphasizing fundamental analysis [1]. Group 2 - The author seeks U.S. companies with solid capital structures, clear growth potential, and efficient, trustworthy management teams [1].